Sec Form 13D Filing - J.P. Morgan Investment Management Inc. filing for JPMorgan Private Markets FundJPMorgan Private Markets Fund - 2023-09-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

JPMorgan Private Markets Fund

(Name of Issuer)

Class I common shares of beneficial interest

(Title of Class of Securities)

48130F306

(CUSIP Number)

Tyler Jayroe

c/o J.P. Morgan Investment Management Inc.

277 Park Avenue

New York, NY 10172

212-270-6000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 18, 2023

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d–1(e), 240.13d–1(f) or 240.13d–1(g), check the following box.  ☐

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d–7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

2

Explanatory Note

This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) is being filed by J.P. Morgan Investment Management Inc. (“JPMIM” or the “Reporting Person”) and amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission on July 24, 2023 (as amended, the “Schedule 13D”) related to the Class I common shares of beneficial interest (the “Class I Common Shares”) of JPMorgan Private Markets Fund, a Delaware statutory trust (the “Issuer”). The Issuer’s principal executive offices are located at 277 Park Avenue, New York, New York 10172. The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

On September 1, 2023, JPMIM’s subscription to purchase Class I Common Shares at the Issuer’s net asset value per Class I Common Share as of August 31, 2023 was accepted by the Issuer (the “September Subscription”). On September 18, 2023, the number of shares being purchased by JPMIM was fixed when the purchase price per share was determined by the Issuer following the determination of the Issuer’s net asset value as of August 31, 2023. Specifically, JPMIM purchased 3,656,010.074 Class I Common Shares as of September 1, 2023 for an aggregate purchase price of $45,000,000, or $12.3085 per Class I Common Share. The purchase closed on September 18, 2023. The Class I Common Shares were paid for from JPMIM’s working capital.

Item 5 (a) – (c) of the Schedule 13D is hereby amended and restated as follows:

The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5.

(a) and (b) As of the date hereof, JPMIM may be deemed to beneficially own an aggregate of 4,186,260.074 Class I Common Shares representing approximately 49.8% of the outstanding Class I Common Shares. The percentage of beneficial ownership in this Schedule 13D assumes that there are 8,398,982.187 Class I Common Shares outstanding following the closing based on information received from the Issuer.

(c) Except as otherwise set forth in this Schedule 13D, neither the Reporting Person or, to the best knowledge of such person, the persons named in Annex A, has effected any transactions in the Class I Common Shares during the past 60 days.

3

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 20, 2023